The Role of the Pathologist in Renal Cell Carcinoma Management

Hematol Oncol Clin North Am. 2023 Oct;37(5):849-862. doi: 10.1016/j.hoc.2023.04.014. Epub 2023 May 29.

Abstract

Recent advances in our understanding of the molecular alterations underlying different types of renal cell carcinoma (RCC), as well as the implementation of immune checkpoint inhibitors in the treatment of patients with advanced disease, have significantly expanded the role of pathologists in the management of RCC patients and in the identification of predictive biomarkers that can guide patient treatment. In this chapter, we examine pathologists' evolving role in patient care and the development of precision medicine strategies for RCC.

Keywords: Biomarker; Classification; Immune checkpoints; Immunohistochemistry; PD-1; PD-L1; Pathology; Renal cell carcinoma.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • B7-H1 Antigen
  • Biomarkers
  • Biomarkers, Tumor / genetics
  • Carcinoma, Renal Cell* / drug therapy
  • Carcinoma, Renal Cell* / genetics
  • Humans
  • Kidney Neoplasms* / drug therapy
  • Kidney Neoplasms* / genetics
  • Pathologists

Substances

  • Biomarkers
  • B7-H1 Antigen
  • Biomarkers, Tumor